• Investors
  • News
  • Contact
Iconovo
  • About us
    • Board of Directors
    • Management
    • Our Team
    • Sustainability
    • Career
  • Products
    • Products
    • ICOres
    • ICOcap
    • ICOpre
    • ICOone
    • ICOone Nasal
    • Patents
  • Capabilities
    • Capabilities
    • Devices
    • Formulation
    • Characterization
    • General Support
  • Collaborations
  • Insights
    • Meet us at CPHI 2022
    • Replacing injections with inhalation
    • Boost your business with an innovative inhaler partner
  • Search
  • Menu Menu
  • LinkedIn
  • Twitter

Boost your business with an innovative inhaler partner

Development of inhalation products

The development of inhalation products is very complex and therefore seen as time consuming and associated with a high risk. The interaction between user requirements, performance and regulatory and manufacturing requirements, proofs to be too challenging for most pharmaceutical companies. The market for inhaled pharmaceuticals presents a great business opportunity and there are new therapeutic areas for inhaled therapy, for example vaccination and allergy.

The market for inhaled pharmaceuticals presents a great business opportunity and there are new therapeutic areas for inhaled therapy, for example vaccination and allergy.

Collaboration with Iconovo will give the customer a unique inhaler product at reduced project risk. Iconovo has significant experience and expertise in developing inhaler products together with innovative pharmaceutical companies.

customized inhaler platform

Shorter time to market with a customized inhaler platform

In the next few years, the patents will expire for many best-selling inhaled medicines. For generic inhalation products, you need a new inhaler that does not infringe on the original manufacturer’s patent, and that you formulate the drug substances so that they work together with the new inhaler. The time to first clinical study is critical and the manufacture of clinical study material must be quick and smooth.

Learn more

Reduce development risk with the right expertise

Inhalation is often used to treat conditions in the respiratory system and the lungs, for example COPD or asthma. The interaction between the pharmaceutical and the inhaler device is complex and requires both formulation and design expertise. Iconovo has significant experience and expertise in developing inhaler products together with innovative pharmaceutical companies.

Learn more

Bring inhalation expertise to your business

Both originator and generic drug companies can benefit from proprietary inhaler platforms and formulation development expertise. By partnering with Iconovo, companies do not have  to build up in-house product development expertise, reducing costs and shortening lead times to market launches of their products. Iconovo inhalers are equally well suited for brand new types of drugs as for generic products.

Learn more

WHITE PAPER

Why are inhalation devices so difficult to develop?

Fill in the form to get to the download page.

Your email-address is safe with us, we will not spam you. You will receive 4 newsletters per year with relevant news on inhaled medicine. Enjoy the white paper and feel free to reach out to us.

    Want to be up to date with with our platforms and news in inhalation?

    Sign up for our newsletters now!

    You can trust us with your email-address. We will send you four newsletters per year with news on our platforms. No more, no less.

    Possessing a unique combination

    of engineering and pharma expertise, Iconovo can provide the optimal combination of customized inhalers and tailored formulations.

    ICONOVO AB

    VISITING ADDRESS
    Ideon, Delta 6 Lund
    Ideongatan 3B

    POSTAL ADDRESS
    Iconovo AB
    Ideongatan 3A-B
    SE-223 70 LUND
    Sweden

    CONTACT

    Phone: +46 46 275 67 77

    VP Business Development
    Roger Lassing
    Mail: roger.lassing@iconovo.se

    CEO
    Johan Wäborg
    Mail: johan.waborg@iconovo.se

    SITEMAP

    • Home
    • Capabilities
    • Investors

    Press releases

    Subscribe

    Follow us on Linkedin

    Scroll to top